Impact of Local Tissue Inflammation on Intramyocardial Conduction Pathways Post Percutaneous Valve : Evaluation by Positron Emission Tomography on Exploratory Cohort

Inclusion Criteria: * Major patient (\>18 years of age); * Patient with aortic stenosis defined by aortic valve area ≤ 1cm2 (or indexed aortic valve area ≤ 0.6 cm2/m2 body surface area), OR transvalvular peak velocity ≥ 4 m/s OR transvalvular mean gradient ≥ 40 mmHg, as assessed by transthoracic echocardiography performed in a patient at rest; * Symptomatic patient with: dyspnea ≥ New-York Heart Association (NYHA) stage 2 OR pathological stress test with onset of symptoms on exertion, blood pressure drop, or rhythm disorder on exertion OR Asymptomatic with Left Ventricular Ejection Fraction \< 50% ; * Patient with vascular anatomy compatible with percutaneous femoral valve implantation; * Patient affiliated to or benefiting from a health insurance plan; * Patient who has provided free, informed and written consent. Exclusion Criteria: * Patient with a pacemaker or triple chamber defibrillator prior to TAVI implantation; * Patient with a uni or bicuspid aortic valve; * Patient with severe left ventricular dysfunction LVEF \< 30%; * Patient with other significant valve disease : aortic insufficiency ≥ grade 3, mitral insufficiency ≥ grade 3 or tight mitral stenosis ; * Patient with iliofemoral vascular anatomy preventing safe passage of the valve; * Patient with a pre-existing bioprosthesis or mechanical prosthesis at TAVI in any position; * Inability or refusal to consent; * Pregnant or breastfeeding woman; * Patient under judicial protection or family habilitation; * Patient deprived of liberty by judicial or administrative decision, under guardianship or curatorship; * Patient with life expectancy \< 12 months.